Company Overview and News

 
MHK / Mohawk Industries, Inc. DEF 14A

2018-04-06 sec.gov
DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement
Upvote Downvote

1
MHK / Mohawk Industries, Inc. 10-K (Annual Report)

2018-02-28 sec.gov
Document UNITED STATES
Upvote Downvote

 
Tracking Ruane, Cunniff, & Goldfarb's Portfolio - Q4 2017 Update

2018-02-26 seekingalpha
Ruane, Cunniff, & Goldfarb’s 13F portfolio value increased ~7% from $11.42B to $12.20B. The number of positions decreased from 69 to 66.
Upvote Downvote

2
Tracking Larry Robbins' Glenview Capital Management Portfolio - Q4 2017 Update

2018-02-24 seekingalpha
Glenview Capital Management's 13F portfolio value increased from $17.23B to $18.50B this quarter. The number of positions increased from 56 to 58.
Upvote Downvote

8
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q4 2017 Update

2018-02-22 seekingalpha
Halvorsen's 13F portfolio value increased from $15.44B to $16.26B. The number of positions remained steady at 59.
Upvote Downvote

8
Tracking Dan Loeb's Third Point Portfolio - Q4 2017 Update

2018-02-22 seekingalpha
Dan Loeb's 13F portfolio value increased from $11.90B to $13.86B this quarter. The number of positions increased from 37 to 44.
Upvote Downvote

15
Tracking David Tepper's Appaloosa Management Portfolio - Q4 2017 Update

2018-02-21 seekingalpha
Appaloosa increased Micron Technology, Facebook, Powershares QQQ ETF, & Apple while reducing Alphabet, Energy Transfer Partners LP, and Williams Partners LP.
Upvote Downvote

 
Is Mohawk Industries (MHK) a Great Stock for Value Investors?

2018-02-14 zacks
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value? One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process.
Upvote Downvote

 
More Consumer Sector Earnings Released Last Week

2018-02-14 editors.aws.marketrealist
General Motors (GM) announced its fiscal 4Q17 results on February 6. The revenue declined 14.1% YoY (year-over-year) to $37.7 billion—compared to $43.9 billion in 4Q16. The EPS (earnings per share) increased ~29% YoY to $1.65—compared to $1.28 in 4Q16. The revenue and EPS surpassed the consensus estimates by 3.2% and 20%, respectively.
Upvote Downvote

 
MHK / Mohawk Industries, Inc. / FMR LLC / Fidelity - 3G (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 0 MOHAWK INDUSTRIES INC COMMON STOCK Cusip #608190104 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #608190104 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 476,335 Item 6: 0 Item 7: 3,826,280 Item 8: 0 Item 9: 3,826,280 Item 11: 5.
Upvote Downvote

 
MHK / Mohawk Industries, Inc. / FMR LLC / Fidelity - 3G (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 0 MOHAWK INDUSTRIES INC COMMON STOCK Cusip #608190104 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #608190104 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 476,335 Item 6: 0 Item 7: 3,826,280 Item 8: 0 Item 9: 3,826,280 Item 11: 5.
Upvote Downvote

 
MHK / Mohawk Industries, Inc. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-09 sec.gov
mohawkindustriesinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 4 )*       Name of issuer:  Mohawk Industries Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  608190104     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (
Upvote Downvote

 
MHK / Mohawk Industries, Inc. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-09 sec.gov
mohawkindustriesinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 4 )*       Name of issuer:  Mohawk Industries Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  608190104     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (
Upvote Downvote

 
Stock Market News For Feb 9, 2018

2018-02-09 zacks
Markets slipped into a correction on Thursday after a 1,000 point decline in the Dow. Both the S&P 500 and the blue-chip index closed 10% below their respective record closes on Jan 26. Further, the CBOE Volatility Index surged once again after declining for two straight sessions. Meanwhile, market watchers speculated a possible government shutdown would ensue if the budget deal is not passed by the Senate.
Upvote Downvote

 
Mohawk (MHK) Beats Q4 Earnings, International Business Solid

2018-02-09 zacks
Mohawk Industries, Inc.’s (MHK - Free Report) fourth-quarter adjusted earnings per share (EPS) of $3.42 beat the Zacks Consensus Estimate of $3.33 by 2.7%. Earnings also increased 5% year over year on higher sales and improved productivity. Total revenues of $2.37 billion missed the Zacks Consensus Estimate of $2.38 billion. Revenues, however, increased 8.5% year over year on higher sales across all segments.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 608190104